After hosting a series of investor meetings with senior management, Cantor Fitzgerald analyst Steven Halper reiterates an Overweight rating on Tabula Rasa HealthCare with a $99 price target. The analyst believes Tabula's growth potential is underappreciated and that management's strategy to offer a full suite of clinical applications to improve medication therapy management should be successful over time. Specifically, the fit with SinfoniaRx and PrescribeWellness will drive more health plan customers, Halper tells investors in a research note. In addition, results of the ongoing Centers for Medicare & Medicaid Services pilot to evaluate Enhanced Medication Therapy Management for Medicare patients "continue to show strong cost savings," adds the analyst.